Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Fires Warning Letter To Sun Pharma; Says Corrections At Cranbury Site Inadequate

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Sun Pharmaceuticals - India's largest company by market capitalization - has been issued a warning letter by U.S. FDA for significant violations of good manufacturing practices at its Cranbury-based manufacturing site
Advertisement

Related Content

Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader
After U.S. FDA Action, Investors Take Caraco To Court Alleging Violation Of Securities Laws
After U.S. FDA Action, Investors Take Caraco To Court Alleging Violation Of Securities Laws
Advertisement
UsernamePublicRestriction

Register

SC075794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel